Stock Events

Stock Events

Search...

Oncopeptides AB

$0.27

14

+$0+0% Tuesday 20:00

Statistics

Day High

0.27

Day Low

0.27

52W High

0.85

52W Low

0.27

Volume

200

Avg. Volume

0

Mkt Cap

55.98M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7NovExpected

Q4 2021

Q1 2022

Q2 2022

Q3 2022

Q1 2024

Q2 2024

Next

-5.23

-3.5

-1.77

-0.05

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONPPF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

Bristol-Myers Squibb competes in the oncology space with a broad portfolio of drugs that could be used in similar indications as Oncopeptides' therapies.

Johnson & Johnson

Johnson & Johnson, through its subsidiary Janssen, develops multiple myeloma treatments that directly compete with Oncopeptides' products.

Amgen has a strong presence in the oncology market, including treatments for multiple myeloma, making it a direct competitor.

Gilead Sciences

Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, including therapies that could compete in the same space as Oncopeptides.

Novartis offers several cancer treatments, including therapies for multiple myeloma, positioning it as a competitor.

Pfizer has a growing oncology division with treatments that could compete against Oncopeptides' pipeline.

AbbVie, with its broad oncology portfolio, including therapies for hematologic cancers, competes in the same market as Oncopeptides.

Merck & Co.'s strong oncology pipeline, including treatments for various cancers, makes it a competitor.

Takeda Pharmaceutical

Takeda Pharmaceutical, with its acquisition of Shire, has strengthened its position in the oncology market, including treatments for multiple myeloma, competing with Oncopeptides.

About

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Show more...

CEO

Jakob Lindberg

Employees

67

Country

SE

ISIN

SE0009414576

Listings